Navigation Links
NeurogesX Reports Third Quarter 2009 Results
Date:11/6/2009

ng on November 16, 2009 by dialing 1-877-660-6853 (USA) or 1-201-612-7415 (International), Account Number: 3055, Conference ID Number: 336156. A replay of the webcast will also be available on the corporate website for one month, through December 6, 2009.

About NeurogesX, Inc.

NeurogesX (Nasdaq: NGSX) is a biopharmaceutical company focused on developing and commercializing novel pain management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate Qutenza(TM), a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions. Qutenza is currently approved in the European Union for the treatment of neuropathic pain in non-diabetic adults, either alone or in combination with other medicinal products for pain. Qutenza will be marketed in the European Union, Switzerland, Norway, Iceland, Liechtenstein and certain countries in Eastern Europe, the Middle East and Africa, by Astellas Pharma Europe, Ltd. In the United States, NeurogesX submitted a new drug application (NDA) for PHN to the U.S. Food and Drug Administration (FDA) which was accepted for filing by the FDA in December 2008 and has been given an extended Prescription Drug User Fee Act (PDUFA) date of November 16, 2009.

NeurogesX' second most advanced product candidate, NGX-1998, is a topically applied, liquid formulation containing a high concentration of capsaicin designed to treat pain associated with neuropathic pain conditions. NGX-1998 has completed three Phase 1 studies and NeurogesX is currently planning the design and timing of this program.

NeurogesX' early stage product pipeline includes pre-clinic
'/>"/>

SOURCE NeurogesX
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. NeurogesX to Present at Two November Conferences
2. NeurogesX to Present at UBS Global Life Sciences Conference
3. NeurogesX to Present at Upcoming Fall Conferences
4. NeurogesX Appoints New Board Director and Audit Committee Chairman
5. NeurogesX Reports Second Quarter 2009 Results
6. NeurogesX Announces New PDUFA Date for Qutenza(TM) New Drug Application
7. NeurogesX to Hold Conference Call to Discuss Second Quarter 2009 Financial Results
8. NeurogesX Added to Russell 3000 Index
9. NeurogesX Provides U.S. Regulatory Update for Qutenza(TM)
10. NeurogesX to Present at Needham Life Sciences Conference
11. NeurogesX Receives European Commission Approval for Qutenza(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... The report “Pharmacy Automation Systems Market by ... Systems, Table-top Counters) by End-user (Inpatient Pharmacy Automation, ... to 2019” analyzes and studies the major market ... Asia-Pacific, and the Rest of the World (RoW). ... spread through 300 pages and in-depth TOC on ...
(Date:10/20/2014)... - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced ... $5.8 million and provides a good start to Q4.  The orders ... and one in the Middle East ... levels," said Peter Bruijns , President & CEO. "Total bidding ... than they have been for any complete year since the company ...
(Date:10/20/2014)... October 20, 2014 OncLive® ... Kimmel Cancer Center at Thomas Jefferson University has ... Through the Strategic Alliance Partnership program, the Sidney ... collaborate to raise awareness of the Center’s cutting-edge ... other projects. Clinicians and other health care professionals ...
(Date:10/19/2014)... October 20, 2014 OCTOBER ... Meeting (ABIM). ABIM will take place ... information about ABIM 2014 is now available ... Delegates representing companies and organizations from all ... obtain information on the latest products and ...
Breaking Biology Technology:Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 4Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3
... ... to First Registrants , ... Westborough, MA (PRWEB) -- GenomeQuest, the world leader in sequence data management (SDM), ... a web cloud service to researchers around the world. , , , , ,The ...
... 10 Today, US Oncology, Inc . ... president and general counsel, will be departing from the Company, ... , Watts has had a long and rich history with ... providing legal services and consultation as an outside attorney before ...
... Nov. 10 DATATRAK International, Inc. (OTCQX: DATA), a ... for the clinical trials industry, today announced the award ... client, Symbio, LLC. A CRO specializing in dermatology, ... double data entry and EDC. In an effort ...
Cached Biology Technology:GenomeQuest Places ChIP-Seq Workflow Solution On SDM “Cloud” 2GenomeQuest Places ChIP-Seq Workflow Solution On SDM “Cloud” 3GenomeQuest Places ChIP-Seq Workflow Solution On SDM “Cloud” 4US Oncology Announces Retirement of General Counsel Phil Watts 2DATATRAK Signs New Client for Rescue Study 2DATATRAK Signs New Client for Rescue Study 3DATATRAK Signs New Client for Rescue Study 4
(Date:10/14/2014)... ATHENS, Ohio (Oct. 14, 2014)—It,s been millions of years ... but a team led by Ohio University scientists is ... to model airflow through dinosaur snouts. The research has ... not only breathe but to enhance the sense of ... pretty ,nosy, animals," said Ohio University doctoral student Jason ...
(Date:10/14/2014)... has discovered a new kind of stem cell that can ... liver blood vessels, according to a study published today in ... such a cell type contradicts current theory on how organs ... clues to origins of, and future treatment for, liver cancer., ... into a complex being made up of more than 200 ...
(Date:10/14/2014)... WORCESTER, MA – A team of scientists led ... School (UMMS) and the University of Miami Miller ... likely a key genetic pathway underlying bipolar (manic ... better drugs for treating bipolar affective disorder, as ... , The new findings, published online this week ...
Breaking Biology News(10 mins):Dinosaur breathing study shows that noses enhanced smelling and cooled brain 2Dinosaur breathing study shows that noses enhanced smelling and cooled brain 3Stem cell discovery challenges dogma on how fetus develops; holds insights for liver cancer and reg 2Stem cell discovery challenges dogma on how fetus develops; holds insights for liver cancer and reg 3Rare genetic disease protects against bipolar disorder 2Rare genetic disease protects against bipolar disorder 3
... June 29, 2011 BD Biosciences, a segment ... the availability of BD Recharge™, a chemically defined ... that offers productivity comparable to yeast-based peptones. ... advance for biopharmaceutical cell culture," said Robert Hallenbeck, ...
... A team of North Carolina State University researchers has discovered ... new brain cells in adults does its job. Their findings ... or disease. Most areas of the brain do not ... One exception is the olfactory bulb, the brain,s scent processor, ...
... Jerusalem, Israel The Israeli Chairmanship of EUREKA, the largest ... today in Jerusalem that since the start of Israel,s ... projects have been approved and supported by the program, ... Jerusalem for the fourth and final event held in ...
Cached Biology News:BD Biosciences Introduces Chemically Defined Cell Culture Media Supplement that Increases Biopharmaceutical Protein Production 2Genetic 'conductor' involved with new brain cell production in adults 2EUREKA invested over 300 million euros in industrial initiatives over the past year 2EUREKA invested over 300 million euros in industrial initiatives over the past year 3EUREKA invested over 300 million euros in industrial initiatives over the past year 4
Synaptic Vesicle I Sampler Kit 10g each...
Handles samples from from 75l to 150l...
... phase reagent for Virus ... & unique water insoluble ... detergents and chaotropes; Engineered ... non-envelop viruses while preserving ...
Mouse monoclonal [N7519] to NR0B2 ( Abpromise for all tested applications). Antigen: E.coli expressed recombinant full length protein (Human) NR0B2 Entrez Gene ID: 8431 Swiss Protein ID: ...
Biology Products: